Smith IAN F
SEC-identified person · CIK 1197032 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Foghorn Therapeutics Inc. FHTX | Director | filed 2021–2026 |
| Solid Biosciences, LLC SLDB | Director | filed 2020–2026 |
| Odyssey Therapeutics, Inc. ODTX | Director | filed 2026–2026 |
| Stoke Therapeutics, Inc. STOK | Director · Interim CEO | filed 2023–2026 |
| Vertex Pharmaceuticals INC / MA VRTX | SVP & CFO | filed 2006–2018 |
| Acorda Therapeutics, Inc. ACOR | Director | filed 2007–2018 |
| Infinity Pharmaceuticals, INC. INFI | Director | filed 2008–2018 |
| Ophthotech Corp. OPHT | Director | filed 2016–2016 |
| Epix Pharmaceuticals, Inc. EPIX | Director | filed 2006–2009 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.